The genomics of cardiovascular disorders: therapeutic implications

Related Experiment Video

Updated: Oct 15, 2026

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

P Ferrari1, G Bianchi

  • 1Prassis Sigma-Tau Research Institute, Settimo Milanese, Milan, Italy.

Drugs
|June 14, 2000
PubMed

Insights

Genetic factors significantly influence non-atherosclerotic cardiovascular diseases (CVDs). Understanding gene polymorphisms aids in advanced diagnosis, prevention, and developing targeted therapies for conditions like cardiomyopathies and hypertension.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiology
  • Pharmacogenomics

Background:

  • Cardiovascular disease (CVD) arises from complex gene-environment interactions.
  • Significant advancements have clarified the genetic basis of non-atherosclerotic CVDs.
  • Examples include hypertrophic cardiomyopathy, dilated cardiomyopathy, long-QT syndrome, and essential hypertension.

Purpose of the Study:

  • To summarize current knowledge on major gene polymorphisms associated with specific inherited CVDs.
  • To discuss the implications of discovering disease-associated genes.
  • To explore future directions in diagnosis, prevention, and drug development.

Main Methods:

  • Literature review of genetic polymorphisms in cardiovascular disease.
  • Analysis of current research on gene-environment interactions in CVD.
  • Synthesis of findings related to molecular and cellular functions affected by predisposing genes.

Main Results:

  • Identification of key gene polymorphisms linked to inherited cardiovascular conditions.
  • Demonstration of the link between genetic predispositions and disease development.
  • Highlighting the role of specific genes in conditions like cardiomyopathies and hypertension.

Conclusions:

  • Gene discoveries are crucial for advancing CVD diagnosis and personalized medicine.
  • Understanding genetic underpinnings enables tailored prophylactic strategies.
  • Future drug development can target specific molecular pathways identified through genetic research.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...